Edition:
India

Sun Pharmaceutical Industries Ltd (SUN.BO)

SUN.BO on Bombay Stock Exchange

675.55INR
3:53pm IST
Change (% chg)

Rs11.60 (+1.75%)
Prev Close
Rs663.95
Open
Rs669.00
Day's High
Rs679.70
Day's Low
Rs660.00
Volume
619,331
Avg. Vol
415,832
52-wk High
Rs898.00
52-wk Low
Rs572.40

SUN.BO

Chart for SUN.BO

About

Sun Pharmaceutical Industries Limited is a pharmaceuticals company. The Company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API). Its Rest of World segment includes Western Europe, Canada, Australia, New... (more)

Overall

Beta: 0.32
Market Cap(Mil.): Rs1,593,115.00
Shares Outstanding(Mil.): 2,399.27
Dividend: 1.00
Yield (%): 0.15

Financials

  SUN.BO Industry Sector
P/E (TTM): 21.66 30.04 30.65
EPS (TTM): 30.66 -- --
ROI: 23.32 15.86 15.23
ROE: 22.83 16.96 16.56

India's Sun Pharma says U.S. finds more concerns at Halol plant

MUMBAI Sun Pharmaceutical Industries Ltd, India's largest drugmaker, said on Wednesday the U.S. health regulator has informed the company of more concerns found at its Halol manufacturing plant after a recent inspection.

07 Dec 2016

BRIEF-Sun Pharma Industries launches first branded ophthalmic product Bromsite in USA

* Announcement of launches first branded ophthalmic product Bromsite in USA

28 Nov 2016

MEDIA-Sun Pharma's Mohali unit violated manufacturing norms, finds US FDA - Mint

- Note: Reuters has not verified this story and does not vouch for its accuracy

25 Nov 2016

BRIEF-Sun Pharma enters into deal to buy 85.1 pct of Russia's JSC Biosintez

* Says company has entered into an agreement to acquire 85.1% of JSC Biosintez, a Russian pharmaceutical company

23 Nov 2016

Sun Pharma expects U.S. drug pricing pressures to continue

MUMBAI Sun Pharmaceutical Industries Ltd does not expect pressure on generic drug prices in the United States to abate anytime soon, its managing director said on Thursday, signalling a challenging year ahead in the company's largest market.

10 Nov 2016

UPDATE 2-Sun Pharma expects U.S. drug pricing pressures to continue

* Says expects pricing pressure in U.S. to continue (Adds comments from conference call)

10 Nov 2016

BRIEF-India's Sun Pharma says unsure if Halol plant will be cleared in next 5 months

* India's Sun Pharma said it was unsure if Halol plant would be cleared in the next five months, as the FDA may take time Further company coverage: (Reporting By Zeba Siddiqui)

10 Nov 2016

BRIEF-Sun Pharmaceutical Industries exec says pricing pressure in the U.S. will continue

* Sun Pharmaceutical Industries exec says awaiting US FDA reinspection of Halol plant

10 Nov 2016

India's Sun Pharma Q2 profit beats estimates

MUMBAI, Nov 10 Sun Pharmaceutical Industries Ltd , India's largest drugmaker, reported on Thursday a quarterly profit that more than doubled from last year, outpacing analysts' expectations.

10 Nov 2016

BRIEF-Sun Pharmaceutical Industries approves amalgamation of 4 units into co

* Says approves scheme of amalgamation of Sun Pharma Medisales, Ranbaxy Drugs Ltd, Gufic Pharma, Vidyut Investments into co Source text: http://bit.ly/2g0Jbpb Further company coverage:

10 Nov 2016

Earnings vs. Estimates